Drugs / fostroxacitabine bralpamide
fostroxacitabine bralpamide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03781934 | Sep 2018 → Jan 2025 | hepatocellular carcinoma, intrahepatic cholangiocarcinoma | Medivir | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fostroxacitabine bralpamide | “MIV-818 (fostroxacitabine bralpamide) + pembrolizumab” NCT03781934 ↗ |
| Known as | FOSTROXACITABINE BRALPAMIDE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314416 ↗ |
| Known as | MIV-818 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03781934 ↗ |
| Known as | MIV-818 hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314416 ↗ |
| Modality | Small molecule | — CHEMBL5314416 ↗ |
| Route | Oral | “MIV-818 - oral capsules” NCT03781934 ↗ |